Rubius Therapeutics’ board of directors has approved a plan to liquidate and dissolve the company, the Massachusetts-based biotech announced in an SEC form 8-K filed Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,